These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pemphigus: Current and Future Therapeutic Strategies. Didona D; Maglie R; Eming R; Hertl M Front Immunol; 2019; 10():1418. PubMed ID: 31293582 [TBL] [Abstract][Full Text] [Related]
3. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Pollmann R; Schmidt T; Eming R; Hertl M Clin Rev Allergy Immunol; 2018 Feb; 54(1):1-25. PubMed ID: 29313220 [TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of pemphigus. Tsuruta D; Ishii N; Hashimoto T Immunotherapy; 2012 Jul; 4(7):735-45. PubMed ID: 22853759 [TBL] [Abstract][Full Text] [Related]
5. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay. Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273 [TBL] [Abstract][Full Text] [Related]
6. Pemphigus: a complex T cell-dependent autoimmune disorder leading to acantholysis. Veldman C; Feliciani C Clin Rev Allergy Immunol; 2008 Jun; 34(3):313-20. PubMed ID: 18097775 [TBL] [Abstract][Full Text] [Related]
7. Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: a paradigm of human autoimmunity. Culton DA; Qian Y; Li N; Rubenstein D; Aoki V; Filhio GH; Rivitti EA; Diaz LA J Autoimmun; 2008 Dec; 31(4):311-24. PubMed ID: 18838249 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Mimouni D; Blank M; Payne AS; Anhalt GJ; Avivi C; Barshack I; David M; Shoenfeld Y Clin Exp Immunol; 2010 Dec; 162(3):543-9. PubMed ID: 20964642 [TBL] [Abstract][Full Text] [Related]
9. [Juvenile pemphigus vulgaris]. Janisson-Dargaud D; Reguiaï Z; Perceau G; Eschard C; Bernard P Ann Dermatol Venereol; 2008 Dec; 135(12):843-7. PubMed ID: 19084695 [TBL] [Abstract][Full Text] [Related]
10. Pemphigus. Schmidt E; Kasperkiewicz M; Joly P Lancet; 2019 Sep; 394(10201):882-894. PubMed ID: 31498102 [TBL] [Abstract][Full Text] [Related]
11. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis. Femiano F Minerva Stomatol; 2007 Apr; 56(4):215-23. PubMed ID: 17452959 [TBL] [Abstract][Full Text] [Related]
12. Pemphigus, a pathomechanism of acantholysis. Furue M; Kadono T Australas J Dermatol; 2017 Aug; 58(3):171-173. PubMed ID: 28211055 [TBL] [Abstract][Full Text] [Related]
13. The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. Ding X; Diaz LA; Fairley JA; Giudice GJ; Liu Z J Invest Dermatol; 1999 May; 112(5):739-43. PubMed ID: 10233765 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses. Sami N; Bhol KC; Ahmed AR Clin Exp Immunol; 2001 Sep; 125(3):492-8. PubMed ID: 11531959 [TBL] [Abstract][Full Text] [Related]
15. Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering. Yoshida K; Ishii K; Shimizu A; Yokouchi M; Amagai M; Shiraishi K; Shirakata Y; Stanley JR; Ishiko A J Dermatol Sci; 2017 Mar; 85(3):197-207. PubMed ID: 28024684 [TBL] [Abstract][Full Text] [Related]
16. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just "witnesses of disease"? Amagai M; Ahmed AR; Kitajima Y; Bystryn JC; Milner Y; Gniadecki R; Hertl M; Pincelli C; Kurzen H; Fridkis-Hareli M; Aoyama Y; Frusić-Zlotkin M; Müller E; David M; Mimouni D; Vind-Kezunovic D; Michel B; Mahoney M; Grando S Exp Dermatol; 2006 Oct; 15(10):815-31. PubMed ID: 16984264 [TBL] [Abstract][Full Text] [Related]
17. Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. Buonavoglia A; Leone P; Dammacco R; Di Lernia G; Petruzzi M; Bonamonte D; Vacca A; Racanelli V; Dammacco F Autoimmun Rev; 2019 Apr; 18(4):349-358. PubMed ID: 30738958 [TBL] [Abstract][Full Text] [Related]
18. Desmoglein 3, its pathogenecity and a possibility for therapeutic target in pemphigus vulgaris. Koga H; Tsuruta D; Ohyama B; Ishii N; Hamada T; Ohata C; Furumura M; Hashimoto T Expert Opin Ther Targets; 2013 Mar; 17(3):293-306. PubMed ID: 23294403 [TBL] [Abstract][Full Text] [Related]
19. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. Tavakolpour S; Mahmoudi H; Balighi K; Abedini R; Daneshpazhooh M Int Immunopharmacol; 2018 Jan; 54():131-138. PubMed ID: 29132070 [TBL] [Abstract][Full Text] [Related]
20. Paraneoplastic pemphigus presenting as erythrodermic lichenoid dermatitis with concomitant features of pemphigus foliaceus. Fukumoto T; Shiroyama Y; Niizeki H; Kobayashi N; Asada H; Ishii N; Hashimoto T; Miyagawa S J Dermatol; 2007 Sep; 34(9):645-9. PubMed ID: 17727368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]